Correlation Between Eledon Pharmaceuticals and Petros Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eledon Pharmaceuticals and Petros Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eledon Pharmaceuticals and Petros Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eledon Pharmaceuticals and Petros Pharmaceuticals, you can compare the effects of market volatilities on Eledon Pharmaceuticals and Petros Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eledon Pharmaceuticals with a short position of Petros Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eledon Pharmaceuticals and Petros Pharmaceuticals.

Diversification Opportunities for Eledon Pharmaceuticals and Petros Pharmaceuticals

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Eledon and Petros is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Eledon Pharmaceuticals and Petros Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Petros Pharmaceuticals and Eledon Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eledon Pharmaceuticals are associated (or correlated) with Petros Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Petros Pharmaceuticals has no effect on the direction of Eledon Pharmaceuticals i.e., Eledon Pharmaceuticals and Petros Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eledon Pharmaceuticals and Petros Pharmaceuticals

Given the investment horizon of 90 days Eledon Pharmaceuticals is expected to generate 0.17 times more return on investment than Petros Pharmaceuticals. However, Eledon Pharmaceuticals is 6.04 times less risky than Petros Pharmaceuticals. It trades about -0.08 of its potential returns per unit of risk. Petros Pharmaceuticals is currently generating about -0.04 per unit of risk. If you would invest  414.00  in Eledon Pharmaceuticals on December 28, 2024 and sell it today you would lose (79.00) from holding Eledon Pharmaceuticals or give up 19.08% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Eledon Pharmaceuticals  vs.  Petros Pharmaceuticals

 Performance 
       Timeline  
Eledon Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Eledon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Petros Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Petros Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Eledon Pharmaceuticals and Petros Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eledon Pharmaceuticals and Petros Pharmaceuticals

The main advantage of trading using opposite Eledon Pharmaceuticals and Petros Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eledon Pharmaceuticals position performs unexpectedly, Petros Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Petros Pharmaceuticals will offset losses from the drop in Petros Pharmaceuticals' long position.
The idea behind Eledon Pharmaceuticals and Petros Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Directory
Find actively traded commodities issued by global exchanges
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.